FDA Denies Approval of Lixivaptan, Citing Need for More Information

Posted on November 2, 2012

Lixivaptan will not be approved until the Food and Drug Administration is able to see more data in regards to the drug.  Cornerstone Therapeutics is the company behind the drug, which is meant to treat a condition known as hyponatremia.  This condition is what happens when a person’s blood does not have enough sodium.  An Advisory Committee at first recommended against approval, and the FDA has apparently concurred, saying that there needs to be more information about the drug before approval is allowed.  In addition, the advisory panel came to the unanimous conclusion that the drug should in particular not be used if the hyponatremia condition stems from heart failure.

Click here for more about this rejection.

How Can We Help You?

If you have a legal matter you would like to discuss with an attorney from our firm, please call us at (310) 477-1700 or complete and submit the e-mail form below, and we will get back to you.

  • This field is for validation purposes and should be left unchanged.
  • This field is for validation purposes and should be left unchanged.

*Required Fields